Cochlear

Cochlear Receivables/Revenue

The Receivables to Revenue Ratio of Cochlear (COH.AX) as of Nov 3, 2026 is 21.97 %. In the previous year, Receivables to Revenue Ratio was 19.02 % — a change of 15.47% (higher).

Receivables/Revenue

21.97 %

YoY

15.47%

Last updated:

Receivables to Revenue Ratio of Cochlear is 2025 21.97 % . Receivables to Revenue Ratio of Cochlear was 2024 19.02 % . It decreases by 15.47% higher compared to the previous year.

The Cochlear Receivables/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables/Revenue
Date
Receivables/Revenue
Jan 1, 2018
21.93 AUD
Jan 1, 2019
20.99 AUD
Jan 1, 2020
15.63 AUD
Jan 1, 2021
17.55 AUD
Jan 1, 2022
18.79 AUD
Jan 1, 2023
20.06 AUD
Jan 1, 2024
19.02 AUD
Jan 1, 2025
21.97 AUD
The Cochlear Receivables/Revenue history
YEARReceivables/RevenueYoY
21.97 %+15.47%
19.02 %-5.17%
20.06 %+6.75%
18.79 %+7.07%
17.55 %+12.28%
15.63 %-25.53%
20.99 %-4.29%
21.93 %-0.13%
21.96 %-7.54%
23.75 %-7.12%
25.57 %+2.27%
25.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cochlear Stock analysis

What does Cochlear do? Cochlear Ltd is an Australian-based medical technology company founded in 1981 by engineer Professor Graeme Clark. The company specializes in Cochlear implant systems and other hearing devices. Cochlear Ltd offers accessories, services, and rehabilitation training for individuals with hearing impairments. The company's products are available for both children and adults with varying degrees of hearing loss. Cochlear Ltd operates in different sectors, including Cochlear implant systems, hearing aids, and wireless accessories and streaming systems under the brand names Nucleus® and Baha®. Nucleus® systems utilize a fully implantable cochlear implant and external speech processor to convert sound into electrical signals for interpretation by the brain. Baha® systems are bone-anchored hearing devices for individuals with unilateral to moderate hearing impairments. Cochlear Ltd also provides wireless accessories and streaming systems to connect devices like mobile phones, TVs, and music players to the hearing aids and cochlear implants, improving hearing performance and enhancing social lives. The company has a strong global presence, operating in over 100 countries with headquarters in Australia, multiple production facilities, and research centers. Cochlear Ltd has received numerous awards and recognition for its products and services and is committed to researching and developing new therapies and technologies to improve the lives of individuals with hearing impairments. Cochlear is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cochlear stock

Receivables to Revenue Ratio of Cochlear is 21.97 % in 2025.

Receivables to Revenue Ratio of Cochlear changed from 19.02 % to 21.97 %, representing a 15.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Receivables to Revenue Ratio Cochlear since 2006 – with annual values, charts, and detailed analysis.

The Receivables/Revenue ratio shows what percentage of annual revenue is tied up in accounts receivable. Rising ratios may signal collection issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Receivables to Revenue Ratio's Cochlear with sector peers and the industry average to assess whether it is attractive.

To evaluate Receivables to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Receivables to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Cochlear

All Key Metrics — Cochlear